摘要
目的:探讨大黄酸对大鼠非酒精性脂肪性肝炎(NASH)的影响及其可能的机制。方法:清洁级雄性SD大鼠140～160g24只正常喂养1周后,分成3组,每组8只。对照组以普通饲料喂养;模型组,以高脂高胆固醇饲料喂养(普通饲料+10%猪油+2%胆固醇);治疗组,以高脂高胆固醇饲料喂养,12周后给予大黄酸。于试验第20周处死所有动物。所有动物测体重、肝湿重,计算肝指数;测空腹血糖、转氨酶及血脂水平,放免法测空腹胰岛素水平,计算胰岛素敏感指数;酶法测定丙二醛、谷胱甘肽过氧化物酶水平;HE染色肝病理组织切片。结果:第20周模型组大鼠有胰岛素抵抗及脂质代谢紊乱;血清ALT、AST水平较对照组明显增高;肝组织出现重度脂肪变性,均出现小叶内炎症细胞浸润和散在的灶性坏死;治疗组大鼠的生化指标和脂肪变性及炎症程度较模型组均明显减轻。结论:长期高脂高胆固醇饮食建立的大鼠NASH模型存在胰岛素抵抗,脂质代谢紊乱;大黄酸对大鼠NASH有良好的疗效。
AIM： To explore the therapeutic effect of rhein in rats with nonalcoholic steatohepatitis and its pos, sible mechanism. METHODS： 24 male SD rats were randomly divided into 3 groups after fed with normal diet for 7 days： Control group（n = 8）, fed with normal diet; Model group（ n = 8）, fed with high-fat and high-cholesterol diet （normal diet plus 10% lard and 2% cholesterol） ; Intervention group（ n = 8）, rhein was added orally after 12 weeks fed with high-fat and high-cholesterol diet. M1 the rats were executed after 20 weeks. Body mass, liver weight, transaminase level, blood glucose, triglyceride, cholesteral, insulin level and liver histology were detected. Serum insulin level was measured by radio-immunity technique. The malonaldehyde and glutathione peroxidase activity in live constitution homogenate were measured quantitively. RESULTS： After 20 weeks, the rats in Model group developed lipid metabolic disorder and insulin resistance. The levels of ALT and AST in Model group were higher than those in Control group. Livers presented severe hepatocyte steatosis and the sporadic inflammatory cell infiltration or focal necrosis. There was no significant difference in biochemical index between Intervention group and Control group. Lipid metabolic disorder and insulin resistance of Intervention group were improved, along with the status of hepatocyte steatosis and inflammatory cell infiltration, compared with those in Model group. CONCLUSION： There are significant insulin resistance and lipid metabolic disorder in nonalcoholic steatohepatitis model. Rhein can prevent the development of nonalcoholic steatohepatitis.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2007年第8期923-926,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
